Trending...
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
Webcast scheduled for Monday, July 22 at 8:00 a.m. Eastern Time
CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
More on Ohio Pen
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
More on Ohio Pen
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- New Hair Styles, Cuts, Coloring With Molli's Hair Lab Servicing Amelia, Ohio, Clermont County, OH
- The Self‑Help Expert Launches New Site With Free Personal Growth Tools
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- Over 98% of crypto owners globally don't declare taxes, new report find
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- New Book Reveals The Science Of Predictions
- Breakthrough Generators/Alternators to Unlock Low-Cost, Reliable Power for AI Data Centers
- Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- EFA Announces 2026 Editorial Rate Chart
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- Shoutout Joseph Neibich aka Nybyk
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Best Companies Group Launches Free Best Places to Work in Ohio Program
- A Closer Look at How Buyers Are Navigating Today's Market in Northeast Ohio
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- Age of Steam Roundhouse Museum Announces Opening Day and Grand Christening Event for No. 19
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)